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Verapamil and Ibutilide. Introduction: Early recurrence of atrial  brillation (AF) after cardioversion
may be related to shortening of the atrial effective refractory period (ERP). This study compared the
effects of verapamil and ibutilide on AF cycle length (AFCL), atrial ERP, and susceptibility to recurrent
AF.
Methods and Results: In 33 adults, the atrial ERP was measured at basic drive CLs of 350 and 500 msec
before and after a brief episode of pacing-induced AF. During AF, verapamil, ibutilide, or saline was
infused in 11 patients each. Shortening of the post-AF atrial ERP was attenuated by verapamil and
prevented by ibutilide. AFCL shortened by 32 6 21 msec in the verapamil group (P < 0.01), prolonged
by 44 6 14 msec in the ibutilide group (P < 0.001), and did not change in the control group. AF converted
to sinus rhythm within 10 minutes less often after verapamil (0%) than after ibutilide (82%) or than in
the control group (73%). Post-AF, AF lasting > 10 minutes was induced more often in the verapamil group
than in the ibutilide group (26% vs 0%; P 5 0.01). Another 10 patients received verapamil or ibutilide
in the absence of AF. Atrial ERP was unchanged after verapamil and prolonged after ibutilide.
Conclusion: Verapamil shortens AFCL and impedes the conversion of induced AF, whereas ibutilide
prolongs AFCL and does not impede the early conversion of induced AF. Ibutilide is more effective than
verapamil in preventing post-AF shortening of the atrial ERP and reducing the susceptibility toward
reinduction of AF. (J Cardiovasc Electrophysiol, Vol. 13, pp. 151-157, February 2002)
verapamil, ibutilide, atrial  brillation, atrial refractoriness
Introduction
Atrial  brillation (AF) shortens the atrial effective re-
fractory period (ERP) and increases the susceptibility to
further episodes of AF.1 -3 Previous clinical and experimen-
tal studies demonstrated that verapamil attenuates these
effects of AF.2 ,4 ,5 In accordance with these  ndings, vera-
pamil has been shown to diminish the likelihood of imme-
diate or early recurrence of AF.6 -8 However, in another
study, verapamil did not block the effects of AF on atrial
electrophysiologicproperties.9 Furthermore, verapamil may
make AF more sustained.1 0
Ibutilide is useful for cardioversion of AF and facilitation
of transthoracic cardioversion of AF.11 -13 However, its ef-
fects on atrial electrophysiologic properties in patients with
paroxysmal AF have not been de ned. The purpose of the
present study was to compare the effects of verapamil and
ibutilide on AF, on AF-induced changes in atrial ERP, and
on the susceptibility to reinduction of AF.
Methods
Characteristics of the Study Population
The subjects of this study were 43 patients (7 men and 36
women; mean age 43 17 years; 1 SD) referred to the
University of Michigan Medical Center for radiofrequency
catheter ablation of paroxysmal supraventricular tachycar-
dia (n 42) or idiopathic ventricular tachycardia (n 1).
All patients were in sinus rhythm, and none had a history of
AF. Exclusion criteria consisted of a corrected QT interval
440 msec, presence of structural heart disease, or recent
treatment with amiodarone. Mean left ventricular ejection
fraction was 0.6 0.02.
Study Protocol
Treatment with antiarrhythmic drugs, including digoxin,
beta-blockers, and calcium channel blockers, was discon-
tinued at least  ve half-lives before the electrophysiologic
procedure. The study protocol was approved by the Human
Research Committee and performed with the patient’s con-
sent upon completion of the radiofrequency catheter abla-
tion procedure.
A quadripolar electrode catheter was positioned in the
right atrial appendage,where the mean pacing threshold was
0.8 0.1 mA. Pacing was performed at three times thresh-
old. Atrial ERP was measured at basic drive cycle lengths
(CLs) of 350 and 500 msec using drive trains of eight beats
and a 1-second pause between pacing trains. The initial S1S2
interval was shorter than the ERP, and the S1S2 interval was
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increased in steps of 5 msec until there was atrial capture.
ERP was de ned as the longest S1S2 interval that failed to
result in atrial capture. ERP measurements were repeated at
each basic drive CL until three values were within 5 msec of
each other and then averaged.
Eleven patients were randomized to receive verapamil
0.1 mg/kg intravenously over 3 minutes, followed by an
infusion of 0.005 mg/kg/min over 7 minutes.14 A second
group of 11 patients received ibutilide 0.02 mg/kg intrave-
nously over a period of 10 minutes. This dosage was used
because it provides a balance between optimal ef cacy and
safety, in a weight-adjusted fashion.1 5 The third group of 11
patients served as a control group and received normal
saline 0.3 mL/kg over 10 minutes.
At the onset of drug administration, AF was induced by
rapid atrial pacing at CL 190 msec. Upon conversion to
sinus rhythm, rapid pacing was immediately repeated to
reinduce AF. After $5 minutes of AF, the AF was allowed
to terminate spontaneously. Electrical cardioversion under
deep sedation with midazolam and fentanyl was performed
if the AF persisted for 10 minutes, which was the case in
16 patients. Drug infusion was stopped after 10 minutes or
upon spontaneous cardioversion to sinus rhythm after $5
minutes of AF. Total doses administered were verapamil
10.1 1.7 mg and ibutilide 1.63 0.97 mg. Upon resump-
tion of sinus rhythm, atrial ERP was repeatedly measured at
alternating basic drive CLs of 350 and 500 msec. Elapsed
time between resumption of sinus rhythm and each deter-
mination of atrial ERP was measured to the nearest second.
ERP was measured ten times at each drive CL, for a total of
20 measurements.
To determine the effects of ibutilide and verapamil in the
absence of AF, ibutilide 0.02 mg/kg (mean dose 1.7 0.2
mg) was infused over 10 minutes in  ve patients, and
verapamil 0.1 mg/kg was infused over 3 minutes followed
by an infusion of 0.005 mg/kg/min over 7 minutes (mean
dose 7.8 2.1 mg) in another  ve patients, during sinus
rhythm. Upon completion of the infusion, atrial ERPs were
measured in the same manner as in the patients in whom AF
had been induced.
A secondary episode of AF was de ned as an episode of
AF that was unintentionallyinduced during measurement of
ERP. Whenever a secondary episode of AF was induced,
the elapsed time after resumption of sinus rhythm was noted
and the duration of the episode was measured. In six pa-
tients, a secondary episode of AF persisted for 10 min-
utes, and electrical cardioversion was performed. In these
patients, only the data collected before onset of the second-
ary episode of AF were used for analysis.
Blood pressure was measured with a brachial cuff before
and after AF was induced and did not change signi cantly
or differ between the groups.
Analysis of AFCL
AFCL was measured from two 30-second samples of the
right atrial electrogram obtained immediately after induc-
tion of the primary episode of AF and 30 seconds before
electrical or spontaneous cardioversion of this episode. A
custom-written program in Matlab (MathWorks, Natick,
MA, USA) was used to compute CL. Detection criteria for
electrograms consisted of an amplitude threshold of 10% of
the largest electrogram and an interval 50 msec from the
previous electrogram. The longest and shortest 10% of CLs
were discarded to remove outliers.
Statistical Analysis
Continuous variables are expressed as mean 1 SD.
Groups were compared by analysis of variance with re-
peated measures. Bonferroni test was used for post hoc
analysis. A paired t-test was used to compare the baseline
and  rst post-AF ERPs. Categorical variables were com-




There were no signi cant differences in baseline atrial
ERPs between the verapamil, ibutilide, and control groups,
either at a basic drive CL of 350 msec (P 0.3; Table 1),
or 500 msec (P 0.1; Table 2).
Duration of Induced AF
Mean duration of the primary episode of induced AF was
signi cantly longer in the verapamil group (13.8 4.8 min)
than in the ibutilide group (9.0 4.3 min) or in the control
group (7.5 3.2 min; P 0.001). The primary episode of
AF converted spontaneously within 10 minutes in none of
the 11 patients in the verapamil group, which was signi -
cantly less often than in the ibutilide group (9/11 patients
[82%]; P 0.001), or in the control group (8/11 [73%]; P
0.001).
Mean AFCL
Mean AFCL could be analyzed in 9 patients in the
verapamil group, 8 patients in the ibutilide group, and 8
patients in the control group. During the  rst 30 seconds of
induced AF, mean AFCL was signi cantly shorter in the
verapamil group (155 24 msec) than in the ibutilide
(202 23 msec) and control (198 39 msec; P 0.01)
groups. During the last 30 seconds of induced AF, CL had
shortened signi cantly in the verapamil group (122 13
msec; P 0.003), lengthened signi cantly in the ibutilide
group (241 21 msec; P 0.01), and was unchanged in
the control group (207 32 msec; P 0.4). The AFCL
was 33 21 msec in the verapamil group, 39 25 msec
in the ibutilide group, and 9 25 in the control group
(P 0.001; Figs. 1 and 2).
Change in ERP After AF
Compared with baseline ERP, the  rst post-AF ERP in
the verapamil group was signi cantly shorter at a drive CL
of 350 msec, with rapid subsequent recovery (Table 1 and
Fig. 3). At a drive CL of 500 msec, there was no post-AF
shortening of atrial ERP (Table 2 and Fig. 4). In the ibutilide
group, there was no shortening of atrial ERP at a drive CL
of 350 msec (Table 1 and Fig. 3) or 500 msec (Table 2 and
Fig. 4).
Atrial ERPs in the ibutilide group lengthened and re-
mained longer throughout the post-AF atrial ERP measure-
ment period.
Atrial ERPs in the control group shortened signi cantly
and recovered to a value not signi cantly different from the
baseline measurement 4.2 1.1 minutes after conversion to
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sinus rhythm at a drive CL of 350 msec (Table 1 and Fig. 3)
and 4.8 1.6 minutes after conversion to sinus rhythm at a
drive CL of 500 msec (Table 2 and Fig. 4).
Induction of Secondary Episodes of AF After
Cardioversion
A secondary episode of AF was induced during 7 (5%) of
149 measurements of atrial ERP in the verapamil group, 4
(2%) of 220 measurements in the ibutilide group (P 0.1
vs verapamil), and 32 (16%) of 202 measurements in the
control group (P 0.001 vs verapamil and ibutilide). Mean
duration of secondary episodes of AF was signi cantly
longer in the verapamil group (6.6 6.1 min) than in the
ibutilide (0.3 0.2 min) and control (0.9 2.5 min) groups
(P 0.04).
All post-AF episodes of secondary AF lasting 10 min-
utes were induced during the  rst post-AF measurement of
atrial ERP. This occurred more often in the verapamil group
(26%) than in the ibutilide group (0%; P 0.05), but not
more often than in the control group (5%; P 0.9).
Effects of Verapamil and Ibutilide in the Absence of AF
After infusion of verapamil during sinus rhythm, there
were no changes in atrial ERP at either drive CL (Table 3).
After infusion of ibutilide during sinus rhythm, the  rst
postinfusion atrial ERP was signi cantly longer than base-
line at both drive CLs; atrial ERP then remained unchanged
during subsequent measurements (Table 4).
Discussion
Main Findings
The main  ndings of this study are as follows. (1) Intra-
venous verapamil shortens, whereas ibutilide lengthens, the
CL of induced AF. (2) Verapamil signi cantly prolongs the
duration of induced episodes of AF compared with ibutilide
and control groups. (3) Ibutilide is more effective than
verapamil in preventing the acute effects of a several-
minute episode of AF on the atrial ERP. (4) The suscepti-
Figure 1. Examples of right atrial electrograms sam-
pled during the  rst and last 30 seconds of induced
atrial  brillation after infusion of verapamil, ibutilide,
and saline. Mean atrial  brillation cycle lengths ( 1
SD) are shown.
Figure 2. Mean atrial  brillation (AF) cycle length during the  rst and last
30 seconds of induced AF in the verapamil, ibutilide, and control groups.
Figure 3. Serial measurements of atrial effective refractory period (ERP)
at a basic drive cycle length of 350 ms upon resumption of sinus rhythm
after induced atrial  brillation (AF; hatched box) in the verapamil, ibuti-
lide, and control groups. Mean atrial ERPs are shown. Error bars signify
1 SEM. *P 0.05 vs baseline.
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bility to reinduction of AF episodes lasting 10 minutes
shortly after conversion to sinus rhythm is attenuated to a
greater degree by ibutilide than by verapamil. (5) In the
absence of AF, ibutilide lengthens and verapamil has no
effect on atrial ERP.
Effects on AFCL and Duration
Previous studies demonstrated that AFCL correlates with
atrial ERP.1 6 ,1 7 Therefore, the observation in the present
study that verapamil shortened AFCL implies that it also
shortened atrial ERP. In prior studies, verapamil’s effect on
atrial ERP was measured during sinus rhythm, and vera-
pamil was found to either prolong or have no effect on atrial
ERP.2 ,4 Therefore, the effect of verapamil on atrial refrac-
toriness may be variable, depending on the atrial rate.
Verapamil blocks ICa, resulting in a decrease in the
plateau calcium current and shortening of action potential
duration and ERP.18 However, verapamil also blocks IKr,
thereby lengthening ERP.1 9 The effects of IKr blockade at
relatively slow atrial rates explain why verapamil may
lengthen or have no effect on ERP during sinus rhythm.
However, at rapid rates, ICa blockade by verapamil is en-
hanced,2 0 whereas the effects of IKr blockade are attenu-
ated.21 These rate-dependent effects of verapamil were re-
ported as accounting for the shortening of atrial ERP and
AFCL in dogs2 2 and may explain why verapamil shortened
CL during AF in the present study.
A decrease in atrial ERP during AF in turn shortens the
atrial wavelength, which is the product of refractory period
and conduction velocity.2 3 Shortening of atrial wavelength
promotes the initiation and persistence of AF1 and may
explain why the duration of induced AF in this study was
signi cantly longer in the verapamil group than in the
ibutilide or control groups. A prior study also reported that
verapamil prolongs the duration of AF.10
In line with the results of a prior study 24 and in contrast
to verapamil, ibutilide was found to lengthen the CL of
induced AF, implying that it increased atrial ERP during
AF. In addition, ibutilide resulted in signi cant prolongation
of atrial ERP several minutes after resumption of sinus
rhythm. Furthermore, as found in the present study, prior
studies demonstrated that ibutilide lengthens atrial ERP
during sinus rhythm.2 5 ,2 6 Therefore, in contrast to vera-
pamil, ibutilide appears to consistently prolong atrial refrac-
toriness during sinus rhythm, during AF, and within several
minutes after conversion of AF to sinus rhythm.
Effects of Verapamil and Ibutilide on AF-Induced
Shortening of Atrial ERP
When verapamil was infused during sinus rhythm, atrial
ERP remained unchanged. This indicates that attenuation of
the shortening of ERP by verapamil that occurs post-AF is
attributable to direct antagonism of the effects of AF and not
to direct lengthening of atrial ERP that simply offsets the
AF-induced shortening of ERP.
On the other hand, when ibutilide was infused during
sinus rhythm, atrial ERP quickly lengthened and then re-
mained stable, whereas when it was infused during AF, ERP
gradually lengthened over several minutes to its maximum
value. This suggests that the absence of a change in atrial
ERP immediately upon resumption of sinus rhythm may
Figure 4. Serial measurements of atrial effective refractory period (ERP)
at a basic dive cycle length of 500 ms upon resumption of sinus rhythm
after induced atrial  brillation (AF; hatched box) in the verapamil, ibuti-
lide, and control groups. Format as in Figure 3.
TABLE 3
Effect of Verapamil on Atrial ERP at Basic Drive Cycle Lengths of 350 and 500 msec in the Absence of AF, in Five Patients Each















Baseline 210 18 223 16
Post-drug infusion
1 0.9 0.5 218 13 0.2 1.7 0.7 237 20 0.06
2 2.1 0.7 218 22 0.1 2.7 0.5 232 23 0.3
3 3.4 0.8 216 22 0.2 3.8 0.8 228 27 0.6
4 4.2 0.9 215 20 0.2 4.3 1.4 231 27 0.4
5 5.7 1.2 212 22 0.6 6.1 1.2 231 27 0.3
6 5.9 1.1 213 23 0.5 6.4 1.0 229 26 0.4
7 6.8 1.2 213 26 0.6 7.2 1.2 230 29 0.4
8 7.6 1.2 211 22 0.8 8.0 1.2 228 31 0.6
9 8.4 1.2 212 24 0.17 8.7 1.2 232 31 0.4
10 9.0 1.2 210 24 1.0 9.5 1.3 232 26 0.3
Continuous variables are expressed as mean SD.
AF atrial  brillation; ERP effective refractory period.
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have re ected a direct effect of ibutilide on atrial refracto-
riness that offset the shortening effect of AF on ERP, with
the lengthening effect of ibutilide on refractoriness becom-
ing progressively more manifest as the effects of AF dissi-
pated.
Although verapamil blunted the effect of AF on post-AF
ERP in this study, the magnitude of the effect was not as
great as in a prior study in which verapamil was found to
completely prevent shortening of atrial refractoriness after
an episode of AF.4 There are three possible explanations for
this discrepancy. First, the total dose of verapamil admin-
istered in the present study (10.1 1.7 mg) was lower than
in the prior study (14.7 2.7 mg). Second, the entire dose
of verapamil was infused before the induction of AF in the
prior study but not in the present study. Third, pharmaco-
logic autonomic blockade was used in the prior study,4 but
in the present study, autonomic blockade was not used in
order to more closely mimic a typical clinical scenario. It is
likely that induction of AF and/or transthoracic cardiover-
sion resulted in sympathetic activation,2 7 and a prior study
demonstrated that verapamil’s effects are reversed by beta-
adrenergic stimulation.2 8 These factors may explain why
verapamil did not completely prevent the post-AF shorten-
ing of atrial refractoriness observed in prior studies.
Effects on Susceptibility to Reinduction of AF
Based on the concept of atrial wavelength, prolongation
of atrial ERP diminishes the probability that AF will be
initiated or will be persistent.1 Therefore, the fact that ibuti-
lide prolonged the post-AF atrial ERP compared to baseline,
whereas verapamil simply attenuated the shortening of atrial
ERP observed in the control group, explains why ibutilide
was more effective than verapamil in reducing the suscep-
tibility toward reinduction of episodes of AF lasting 10
minutes shortly after conversion of an episode of AF to
sinus rhythm.
Study Limitations
One limitation of this study is that ERP was measured
only at one site in the right atrium. A second limitation is
that none of the subjects had heart disease; therefore, the
 ndings may not apply to patients with structurally abnor-
mal atria. A third limitation is that the total dosages of
verapamil and ibutilide administered to the subjects in this
study were variable. The intent of this study was to deter-
mine the effects of verapamil and ibutilide administered
during AF, not during sinus rhythm. Because the duration of
AF was variable between subjects and because the drugs
were administered as infusions as opposed to bolus doses,
this limitation was unavoidable.
Conclusion
The  ndings of this study have interesting mechanistic
and clinical implications regarding the effects of verapamil
and ibutilide on AF. Verapamil shortens atrial ERP during
AF but attenuates the shortening of atrial ERP that occurs
upon conversion of AF to sinus rhythm. This explains why
verapamil promotes the continuation of an episode of AF
and yet diminishes the susceptibility toward reinduction of
AF once the original episode has converted to sinus rhythm.
Ibutilide’s effects on atrial refractoriness are opposite to
those of verapamil during AF, yet they are qualitatively
similar during sinus rhythm after an episode of AF. These
 ndings demonstrate that the effects of antiarrhythmic
agents during AF may be dissociated from their immediate
post-AF effects.
A clinical implication of the results of this study is that
intravenously administered verapamil may be a suboptimal
agent for rate control during AF. Although verapamil is
effective in reducing the ventricular rate,29 the  ndings of
this study suggest that verapamil is likely to shorten AFCL,
thereby diminishing the probability of spontaneous conver-
sion to sinus rhythm. It will be important to determine
whether this  nding applies to other calcium channel block-
ers, such as diltiazem, which is commonly used intrave-
nously for acute rate control.
A second clinical implication of the  ndings of this study
has to do with the phenomenon of immediate recurrence of
AF after cardioversion. A recent study demonstrated that
intravenously administered verapamil was effective in
maintaining sinus rhythm in 47% of patients with immedi-
ate recurrences of AF after transthoracic cardioversion.8
TABLE 4
Effect of Ibutilide on Atrial ERP at Basic Drive Cycle Lengths of 350 and 500 msec in the Absence of AF, in Five Patients Each















Baseline 192 19 196 20
Post-drug infusion
1 1.1 0.9 221 30 0.01 1.9 0.8 234 26 0.001
2 2.4 1.0 222 26 0.005 2.9 1.0 234 27 0.001
3 3.3 0.9 221 29 0.01 3.9 1.0 237 34 0.007
4 4.5 1.4 222 24 0.002 5.1 1.6 232 31 0.009
5 5.4 1.6 223 32 0.01 5.9 1.5 230 27 0.004
6 6.3 1.5 224 25 0.003 7.1 1.3 233 27 0.002
7 7.5 1.4 225 29 0.008 7.8 1.4 232 28 0.005
8 8.2 1.4 223 25 0.005 8.7 1.5 231 26 0.003
9 9.1 1.4 219 24 0.004 9.7 1.5 236 23 0.001
10 10.0 1.5 219 19 0.004 10.7 1.5 233 21 0.001
Continuous variables are expressed as mean SD.
AF atrial  brillation; ERP effective refractory period.
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Based on the effects of verapamil and ibutilide on the
susceptibility to pacing-induced AF, the  ndings of this
study suggest that ibutilide may be more effective than
verapamil in preventing immediate recurrences of AF after
cardioversion. This issue also requires additional investiga-
tion.
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